Published by Benjamin Chiou on 20th February 2026
(Sharecast News) - Grail's share price halved on Friday in New York after the American biotech group said that a three-year trial of its Galleri cancer-screening test with the NHS failed to meet its primary endpoint.
URL: http://www.digitallook.com/dl/news/story/35713615/...